The Taizhou Medical High-tech Zone, located in Taizhou city, East China's Jiangsu province, is forging ahead in the development of manufacturing pilot platforms.
An example of this is the Biomedical Research and Development Pilot Platform being operated by biopharma group Jiangsu Huatai Vaccine Engineering Technology Research, which was recently included in the provincial manufacturing pilot platform cultivation library.
Acting as a bridge for new technologies to move from the lab to the market, the pilot platform is crucial in commercializing technological achievements.
The company operates in the vaccines, antibodies and other biopharma fields, providing technical services and support in areas such as R&D, pilot production, drug formulation, quality research, clinical evaluations and technical training.
Its customers include more than 50 leading domestic and international groups such as Johnson & Johnson, Shanghai Fosun Pharmaceutical (Group) and Wantai Biopharm.
An external view of the premises of Jiangsu Huatai Vaccine Engineering Technology Research. [Photo/WeChat account: weigg6666]